Matrix metalloproteinase-9 in broncho-alveolar lavage fluid of patients with non-small cell lung cancer

Exp Oncol. 2006 Jun;28(2):169-71.

Abstract

Aim: To evaluate concentration of MMP-9 in blood plasma and broncho-alveolar lavage fluid (BALF) from patients with non-small cell lung cancer (NSCLC).

Methods: Blood plasma from 40 NSCLC patients and 40 healthy donors was collected and concentrations of blood plasma and BALF MMP-9 were measured using ELISA. Correlation between MMP-9 level and gender, histological type of tumor and stage of disease was analyzed.

Results: Levels of blood plasma MMP-9 were significantly higher in NSCLC patients (p < 0.0001) then in control group, and were especially high in patients with stage IV of disease (stage I vs stage IV - p < 0.005, stage II vs stage IV - p < 0.01, stage III vs stage IV - p < 0.01). Also, stage IV of NSCLC was characterized by the highest level of BALF MMP-9 (stage I vs stage IV - p < 0.002, stage II vs stage IV p < 0.002, and stage III vs stage IV p < 0.007). Correlation between blood plasma and BALF MMP-9 levels and gender or histological type of tumor was insignificant.

Conclusion: Our data revealed significant correlation between tumor stage and BALF and plasma MMP-9 levels in NSCLC patients.

MeSH terms

  • Adult
  • Aged
  • Bronchoalveolar Lavage Fluid / chemistry*
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Female
  • Humans
  • Lung Neoplasms / diagnosis*
  • Male
  • Matrix Metalloproteinase 9 / analysis*
  • Matrix Metalloproteinase 9 / blood
  • Middle Aged
  • Neoplasm Staging

Substances

  • Matrix Metalloproteinase 9